CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

Terminalia arjuna Bark and inotropic therapy for heart failure

  • Liu, Shi Jesse (Department of Pharmaceutical Sciences, and Department of Pharmacology & Toxicology, University of Arkansas for Medical Sciences)
  • Received : 2012.05.21
  • Accepted : 2012.08.21
  • Published : 2012.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Heart disease that ultimately leads to heart failure (HF) has been the number one cause of death in the United States as well as in many other countries for over a century. Inotropic therapy utilizing cardiotonics to increase cardiac contractility remains a significant component of the management of HF. However, adverse effects of currently available cardiotonics have been compromising their therapeutic value and often lead to further myocardial dysfunction. Thus, discovery of safe cardiotonics remains a main challenge to improvement of inotropic therapy for HF. This review briefly summarized cellular mechanisms underlying the inotropic action of currently available cardiotonics, newly-developed carditonics and the bark of Terminalia arjuna (TA), a tropical tree used in ayurvedic medicine. The potential of TA bark as a new cardiotonic in inotropic treatment for HF was also discussed.

Keywords

References

  1. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006;98:102-106. https://doi.org/10.1016/j.amjcard.2006.01.068
  2. Ahern TP, Lash TL, Sorensen HT, Pedersen LA. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res. 2008;10:R102.
  3. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403. https://doi.org/10.1161/CIRCULATIONAHA.106.628347
  4. Akita T, Joyner RW, Lu C, Kumar R, Hartzell HC. Developmental changes in modulation of calcium currents of rabbit ventricular cells by phosphodiesterase inhibitors. Circulation. 1994;90:469-478. https://doi.org/10.1161/01.CIR.90.1.469
  5. Ali A, Kaur G, Hayat K, Ali M, Ather M, Ali A, Kaur G, Hayat K, Ali M, Ather M. A novel naphthanol glycoside from Terminalia arjuna with antioxidant and nitric oxide inhibitory activities. Pharmazie. 2003;58:932-934.
  6. Arispe N, Diaz JC, Simakova O, Pollard HB. Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels. PNAS. 2008;105:2610-2615. https://doi.org/10.1073/pnas.0712270105
  7. Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol. 2008;294:H238-H248.
  8. Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart J. 2002;54:170-175.
  9. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol. 1995;49:191-199. https://doi.org/10.1016/0167-5273(95)02320-V
  10. Braunwald E. The Management of heart failure: the past, the present, and the future. Circ Heart Fail. 2008;1:58-62. https://doi.org/10.1161/CIRCHEARTFAILURE.107.752162
  11. Brixius K, Pietsch M, Hoischen S, Müller-Ehmsen J, Schwinger RHG. Effect of inotropic interventions on contraction and Ca2+ transients in the human heart. J Appl Physiol. 1997;83:652-660. https://doi.org/10.1152/jappl.1997.83.2.652
  12. Campia U, Nodari S, Gheorghiade M. Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Current Heart Fail Rep. 2010;7:100-109. https://doi.org/10.1007/s11897-010-0021-9
  13. Chen Q, Camara AKS, Rhodes SS, Riess ML, Novalija E, Stowe DF. Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts. Cardiovasc Res. 2003;59:912-925. https://doi.org/10.1016/S0008-6363(03)00524-8
  14. Cleland J,GF, Teerlink JR, Senior R, Nifontov EM, Mc Murray J,JV, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. The Lancet. 2011;378:676-683. https://doi.org/10.1016/S0140-6736(11)61126-4
  15. Colucci WS, Sawyer DB, Singh K, Communal C. Adrenergic overload and apoptosis in heart failure: implications for therapy. J Card Fail. 2000;6:1-7. https://doi.org/10.1016/S1071-9164(00)80002-0
  16. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the ${\beta}$-adrenergic pathway. Circulation. 1998;98:1329-1334. https://doi.org/10.1161/01.CIR.98.13.1329
  17. Curran J, Hinton MJ, Rios E, Bers DM, Shannon TR. ${\beta}$-Adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res. 2007;100:391-398. https://doi.org/10.1161/01.RES.0000258172.74570.e6
  18. Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol. 2010;138:281-289. https://doi.org/10.1016/j.ijcard.2008.08.020
  19. Ding B, Abe Ji, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation. 2005;111:2469-2476. https://doi.org/10.1161/01.CIR.0000165128.39715.87
  20. Ding G, Wiegerinck RF, Shen M, Cojoc A, Zeidenweber CM, Wagner MB. Dopamine increases L-type calcium current more in newborn than adult rabbit cardiomyocytes via D1 and ${\beta}2$ receptors. Am J Physiol. 2008;294:H2327-H2335.
  21. Dwivedi S, Aggarwal A, Agarwal MP, Rajpal S. Role of Terminalia arjuna in ischaemic mitral regurgitation. Int J Cardiol. 2005;100:507-508. https://doi.org/10.1016/j.ijcard.2004.10.045
  22. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, Solaro RJ. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77:107-113. https://doi.org/10.1161/01.RES.77.1.107
  23. Endoh M. The effects of various drugs on the myocardial inotropic response. Gen Pharmacol. 1995;26:1-31. https://doi.org/10.1016/0306-3623(94)00144-C
  24. Felker GM, O'Connor CM. Inotropic therapy for heart failure: An evidence-based approach. Am Heart J. 2001;142:393-401. https://doi.org/10.1067/mhj.2001.117606
  25. Gauthaman K, Maulik M, Kumari R, Manchanda SC, Dinda AK, Maulik SK. Effect of chronic treatment with bark of Terminalia arjuna: a study on the isolated ischemic-reperfused rat heart. J Ethnopharmacol. 2001;75:197-201. https://doi.org/10.1016/S0378-8741(01)00183-0
  26. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol. 2005;96:68-73. https://doi.org/10.1016/j.amjcard.2005.07.023
  27. Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Euro Heart J. 2011;32:1838-1845. https://doi.org/10.1093/eurheartj/ehr026
  28. Hatem SN, Coulombe A, Balse E. Specificities of atrial electrophysiology: Clues to a better understanding of cardiac function and the mechanisms of arrhythmias. J Mol Cell Cardiol. 2010;48:90-95. https://doi.org/10.1016/j.yjmcc.2009.08.029
  29. Holubarsch C, Hasenfuss G, Just H, Alpert NR. Positive inotropism and myocardial energetics: Influence of ${\beta}$ receptor agonist stimulation, phosphodiesterase inhibition, and ouabain. Cardiovasc Res. 1994;28:994-1002. https://doi.org/10.1093/cvr/28.7.994
  30. Jain S, Yadav P, Gill V, Vasudeva N, Singla N. Terminalia arjuna a sacred medicinal plant: phytochemical and pharmacological profile. Phytochem Rev. 2009;8:491-502. https://doi.org/10.1007/s11101-009-9134-8
  31. Joseph J, Gilbert EM. The sympathetic nervous system in chronic heart failure. Prog Cardiovasc Dis. 1998;41:9-16. https://doi.org/10.1016/S0033-0620(98)80026-1
  32. Kapur S, Aistrup GL, Sharma R, Kelly JE, Arora R, Zheng J, Veramasuneni M, Kadish AH, Balke CW, Wasserstrom JA. Early development of intracellular calcium cycling defects in intact hearts of spontaneously hypertensive rats. Am J Physiol. 2010;299:H1843-H1853.
  33. Karthikeyan K, Sarala Bai BR, Gauthaman K, Sathish KS, Devaraj SN. Cardioprotective effect of the alcoholic extract of Terminalia arjuna bark in an in vivo model of myocardial ischemic reperfusion injury. Life Sci. 2003;73:2727-2739. https://doi.org/10.1016/S0024-3205(03)00671-4
  34. Katz AM. The "modern" view of heart failure: how did we get here? Circ Heart Fail. 2008;1:63-71. https://doi.org/10.1161/CIRCHEARTFAILURE.108.772756
  35. Korge P, Langer GA. Mitochondrial Ca2+ uptake, efflux, and sarcolemmal damage in Ca2+-overloaded cultured rat cardiomyocytes. Am J Physiol. 1998;274:H2085-H2093.
  36. Kuo PL, Hsu YL, Lin TC, Lin LT, Chang JK, Lin CC. Casuarinin from the bark of Terminalia arjuna induces apoptosis and cell cycle arrest in human breast adenocarcinoma MCF-7 cells. Planta Med. 2005;71:237-243. https://doi.org/10.1055/s-2005-837823
  37. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res. 2005;66:12-21. https://doi.org/10.1016/j.cardiores.2004.12.022
  38. Le Grand B, Deroubaix E, Coulombe A, Coraboeuf E. Stimulatory effect of ouabain on T- and L-type calcium currents in guinea pig cardiac myocytes. Am J Physiol. 1990;258:H1620-H1623.
  39. Lederer WJ, Tsien RW. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibres. J Physiol. 1976;263:73-100. https://doi.org/10.1113/jphysiol.1976.sp011622
  40. Lee CO. 200 years of digitalis: the emerging central role of the sodium ion in the control of cardiac force. Am J Physiol. 1985;249:C367-C378. https://doi.org/10.1152/ajpcell.1985.249.5.C367
  41. Lehnart S, Maier L, Hasenfuss G. Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev. 2009;14:213-224. https://doi.org/10.1007/s10741-009-9146-x
  42. Lucke JC, Elbeery JR, Koutlas TC, Gall SA,Jr., D'Amico TA, Maier GW, Rankin JS, Glower DD. Effects of cardiac glycosides on myocardial function and energetics in conscious dogs. Am J Physiol. 1994;267:H2042-H2049.
  43. Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O'Rourke B. Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res. 2006;99:172-182. https://doi.org/10.1161/01.RES.0000232546.92777.05
  44. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen Y, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-1443. https://doi.org/10.1126/science.1200113
  45. Marban E, Robinson SW, Wier WG. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest. 1986;78:1185-1192. https://doi.org/10.1172/JCI112701
  46. McGarry SJ, Williams AJ. Digoxin activates sarcoplasmic reticulum Ca2+-release channels: A possible role in cardiac inotropy. Br J Pharmacol. 1993;108:1043-1050. https://doi.org/10.1111/j.1476-5381.1993.tb13503.x
  47. Medford RM. Digitalis and the Na+,K(+)-ATPase. Heart Dis Stroke. 1993;2:250-255.
  48. Metra M, Bettari L, Carubelli V, Bugatti S, Dei Cas A, Del Magro F, Lazzarini V, Lombardi C, Dei Cas L. Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. Drugs. 2011;71:515-525. https://doi.org/10.2165/11585480-000000000-00000
  49. Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A, Moro B, Parodi O, Ferrari P, Bianchi G. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol. 2007;99:24A-32A. https://doi.org/10.1016/j.amjcard.2006.09.003
  50. Miller AL. Botanical influences on cardiovascular disease. Altern Med Rev. 1998;3:422-431.
  51. Nagpal A, Meena L, Kaur S, Grover I, Wadhwa R, Kaul S. Growth suppression of human transformed cells by treatment with bark extracts from a medicinal plant, Terminalia arjuna. In Vitro Cell & Devel Biol - Animal. 2000;36:544-547. https://doi.org/10.1290/1071-2690(2000)036<0544:GSOHTC>2.0.CO;2
  52. Nam GB, Burashnikov A, Antzelevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation. 2005;111:2727-2733. https://doi.org/10.1161/CIRCULATIONAHA.104.479295
  53. Nammi S, Gudavalli R, Babu BS, Lodagala DS, Boini KM, Nammi S, Gudavalli R, Babu B,S.Ravindra, Lodagala DS, Boini KM. Possible mechanisms of hypotension produced 70% alcoholic extract of Terminalia arjuna (L.) in anaesthetized Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, Breyne B. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. Eur J Clin Pharmacol. 1994;46:191-196. https://doi.org/10.1007/BF00192547
  54. Oberoi L, Akiyama T, Lee KH, Liu SJ. The aqueous extract, not organic extracts, of Terminalia arjuna bark exerts cardiotonic effect on adult ventricular myocytes. Phytomed. 2011;18:259-265. https://doi.org/10.1016/j.phymed.2010.07.006
  55. O'Connor CM, Gattis WA, Uretsky BF, Adams Jr KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78-86. https://doi.org/10.1016/S0002-8703(99)70250-4
  56. Osadchii OE, Norton GR, McKechnie R, Deftereos D, Woodiwiss AJ. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic ${\beta}$-adrenoreceptor activation. Am J Physiol Heart Circ Physiol. 2007;292:H1898-H1905. https://doi.org/10.1152/ajpheart.00740.2006
  57. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475. https://doi.org/10.1056/NEJM199111213252103
  58. Pawar RS, Bhutani KK. Effect of oleanane triterpenoids from Terminalia arjuna - a cardioprotective drug on the process of respiratory oxyburst. Phytomed. 2005;12:391-393. https://doi.org/10.1016/j.phymed.2003.11.007
  59. Radhakrishnan R, Wadsworth RM, Gray AI. Terminalia arjuna, an ayurvedic cardiotonic, increases contractile force of rat isolated atria. Phytother Res. 1993;7:266-268. https://doi.org/10.1002/ptr.2650070314
  60. Rendig SV, Amsterdam EA. Comparison of positive inotropic effects of milrinone, dobutamine and ouabain. Cardiology. 1994;84:99-105.
  61. Rocchetti M, Alemanni M, Mostacciuolo G, Barassi P, Altomare C, Chisci R, Micheletti R, Ferrari P, Zaza A. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (e,z)-3-((2-aminoethoxy)imino) androstane-6,17- dione hydrochloride)] in a pressure-overload heart failure model. J Pharmacol Exp Ther. 2008;326:957-965. https://doi.org/10.1124/jpet.108.138701
  62. Rocchetti M, Besana A, Mostacciuolo G, Micheletti R, Ferrari P, Sarkozi S, Szegedi C, Jona I, Zaza A. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: Digoxin and PST2744 [(E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydr- ochloride]. J Pharmacol Exp Ther. 2005;313:207-215.
  63. Rosca MG, Hoppel CL. Mitochondria in heart failure. Cardiovasc Res. 2010;88:40-50. https://doi.org/10.1093/cvr/cvq240
  64. Ruch SR, Nishio M, Wasserstrom JA. Effect of cardiac glycosides on action potential characteristics and contractility in cat ventricular myocytes: Role of calcium overload. J Pharmacol Exp Ther. 2003;307:419-428. https://doi.org/10.1124/jpet.103.049189
  65. Sagawa T, Sagawa K, Kelly JE, Tsushima RG, Wasserstrom JA. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol. 2002;282:H1118-H1126. https://doi.org/10.1152/ajpheart.00700.2001
  66. Shen Y, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure / clinical perspective. Circ Heart Fail. 2010;3:522-527. https://doi.org/10.1161/CIRCHEARTFAILURE.109.930321
  67. Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN, Sonnenblick EH. ${\beta}$-Adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol. 1998;275:H961-H968.
  68. Singh DV, Gupta MM, Tripathi AK, Prajapati V, Kumar S. Arjunetin from Terminalia arjuna as an insect feeding-deterrent and growth inhibitor. Phytother Res. 2004;18:131-134. https://doi.org/10.1002/ptr.1383
  69. Singh N, Kapur KK, Singh SP, Shanker K, Sinha JN, Kohli RP. Mechanism of cardiovascular action of Terminalia arjuna. Planta Med. 1982;45:102-104. https://doi.org/10.1055/s-2007-971255
  70. Sivalokanathan S, Vijayababu MR, Balasubramanian MP. Effects of Terminalia arjuna bark extract on apoptosis of human hepatoma cell line HepG2. World J Gastroenterol. 2006;12:1018-1024. https://doi.org/10.3748/wjg.v12.i7.1018
  71. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I. Binding of Levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337-9343. https://doi.org/10.1074/jbc.M007484200
  72. Stevenson LW. Inotropic therapy for heart failure. N Engl J Med. 1998;339:1848-1850. https://doi.org/10.1056/NEJM199812173392511
  73. Stump GL, Wallace AA, Gilberto DB, Gehret JR, Lynch JJ,Jr. Arrhythmogenic potential of positive inotropic agents. Basic Res Cardiol. 2000;95:186-198. https://doi.org/10.1007/s003950050181
  74. Teerlink J. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. 2009;14:289-298. https://doi.org/10.1007/s10741-009-9135-0
  75. Teerlink J, Metra M, Zaca V, Sabbah H, Cotter G, Gheorghiade M, Cas L. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev. 2009;14:243-253. https://doi.org/10.1007/s10741-009-9153-y
  76. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533. https://doi.org/10.1056/NEJM199702203360801
  77. Toma M, Starling R. Inotropic therapy for end-stage heart failure patients. Curr Treat Options in Cardiovas Med. 2010;12:409-419. https://doi.org/10.1007/s11936-010-0090-9
  78. Tomita H, Nazmy M, Kajimoto K, Yehia G, Molina CA, Sadoshima J. Inducible cAMP early repressor (icer) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to ${\beta}$-adrenergic receptor stimulation. Circ Res. 2003;93:12-22. https://doi.org/10.1161/01.RES.0000079794.57578.F1
  79. Trautwein W, Hescheler J. Regulation of cardiac L-type calcium current by phosphorylation and G proteins. Annu Rev Physiol. 1990;52:257-274. https://doi.org/10.1146/annurev.ph.52.030190.001353
  80. Tweedie D, Harding SE, MacLeod KT. Sarcoplasmic reticulum Ca content, sarcolemmal Ca influx and the genesis of arrhythmias in isolated guinea-pig cardiomyocytes. J Mol Cell Cardiol. 2000;32:261-272. https://doi.org/10.1006/jmcc.1999.1070
  81. Verkerk AO, Veldkamp MW, Baartscheer A, Schumacher CA, Klopping C, van Ginneken ACG, Ravesloot JH. Ionic mechanism of delayed afterdepolarizations in ventricular cells isolated from human end-stage failing hearts. Circulation. 2001;104:2728-2733. https://doi.org/10.1161/hc4701.099577
  82. Wakita Y. Inotropic, Chronotropic, and Arrhythmogenic Effects of dopamine on the isolated working heart of rabbit. J Physiol Sci. 2007;57:147-157. https://doi.org/10.2170/physiolsci.RP003607
  83. Wier WG, Hess P. Excitation-contraction coupling in cardiac Purkinje fibers. Effects of cardiotonic steroids on the intracellular [Ca2+] transient, membrane potential, and contraction. J Gen Physiol. 1984;83:395-415. https://doi.org/10.1085/jgp.83.3.395
  84. Yano M, Kohno M, Ohkusa T, Mochizuki M, Yamada J, Hisaoka T, Ono K, Tanigawa T, Kobayashi S, Matsuzaki M. Effect of milrinone on left ventricular relaxation and Ca2+ uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol. 2000;279:H1898-H1905. https://doi.org/10.1152/ajpheart.2000.279.4.H1898
  85. Yatani A, Brown AM. Rapid ${\beta}$-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science. 1989;245:71-74. https://doi.org/10.1126/science.2544999
  86. Zhao H, Matsuoka s, Fujioka Y, Noma A. Effects of dopamine on L-type Ca2+ current in single atrial and ventricular myocytes of the rat. Br J Pharmacol. 1997;121:1247-1254. https://doi.org/10.1038/sj.bjp.0701250